ArQule (ARQL) Reports Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531
Tweet Send to a Friend
ArQule, Inc. (NASDAQ: ARQL) presented preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE